Fulcrum Therapeutics (FULC) Accumulated Depreciation (2018 - 2026)

Fulcrum Therapeutics (FULC) has reported Accumulated Depreciation for 9 consecutive years, with $1.0 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Accumulated Depreciation fell 92.99% year-over-year to $1.0 million; the TTM figure through Jun 2026 stood at $1.0 million (down 92.99% YoY), while the FY2025 annual figure was $15.6 million, up 9.75% from the prior year.
• Accumulated Depreciation eased to $1.0 million in Q2 2026 per FULC's latest filing, from $15.2 million in the prior quarter.
• Across five years, Accumulated Depreciation topped out at $15.6 million in Q4 2025 and bottomed at $1.0 million in Q2 2026.
• Historically, Accumulated Depreciation has averaged $12.2 million across 5 years, with a median of $13.0 million in 2023.
• Annual changes were most pronounced in 2022 — Accumulated Depreciation jumped 31.19% — and 2026, when it tumbled 92.99%.
• Fulcrum Therapeutics' Accumulated Depreciation stood at $10.7 million in 2022, then climbed by 19.68% to $12.8 million in 2023, then gained by 11.73% to $14.3 million in 2024, then climbed by 9.75% to $15.6 million in 2025, then tumbled by 93.3% to $1.0 million in 2026.
• Business Quant data shows FULC's Accumulated Depreciation at $1.0 million in Q2 2026, $15.2 million in Q1 2026, and $15.6 million in Q4 2025.